Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC | MicrobiomeTrials← Back to trialsNCT07639242
Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-06Est. Completion: 2030-06-21
Enrollment target: 60 participants Locations- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Other microbiome trials you might be interested in
Lung Cancer Screening
This is an optimization pathway for lung cancer screening programs. Enrolled programs will undergo an audit for elements…
Jackson, United StatesEst. completion Jun 1, 2027
EGFR OverexpressionLocally Advanced Solid TumorMetastatic Solid Tumor
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Ad…
Seoul, South KoreaEst. completion Jun 2027
Recruiting
MelanomaLi-Fraumeni SyndromePulmonary BlastomaChordomaCongenital Bone Marrow Failure SyndromesCostello SyndromeFanconi AnemiaCFC Syndrome (CFCS)Legius SyndromeRASopathies
Background:
Clinical Genetics Branch (CGB) researchers study individuals and populations at high genetic risk of cancer…
Rockville, United StatesEst. completion Jan 1, 2035